key: cord-0947236-tjtujmsj
authors: Grant, William B.; Lordan, Ronan
title: Vitamin D for COVID-19 on trial: An update on prevention and therapeutic application
date: 2021-10-11
journal: Endocr Pract
DOI: 10.1016/j.eprac.2021.10.001
sha: 88c1e18e517510177be58ae3d62236b59ec8aad8
doc_id: 947236
cord_uid: tjtujmsj

nan

The results of a pilot randomized, placebo-controlled, double-blind clinical trial of calcifediol [25-hydroxyvitamin D (25(OH)D3)] treatment of 106 COVID-19 patients in Iran are presented in an article in this issue (1) . The primary significant effects of calcifediol treatment were an increase in lymphocyte percentage and decrease in the ratio of neutrophils to lymphocytes in the patients. There were also modest trends for hospitalization, intensive care unit (ICU) duration, needing ventilator assistance, and mortality in the calcifediol group compared to the placebo group. This commentary reviews what is known about vitamin D in preventing and treating COVID-19 in order to put this article in perspective.

Calcifediol has the advantage over vitamin D3 supplementation of more rapidly increasing serum 25(OH)D concentration, in a matter of hours rather than days. This property is very important for treating COVID-19 since two main effects of vitamin D regarding COVID-19 are reduced viability and replication of the SARS-CoV-2 virus and reduced risk of the cytokine storm (2) . In fact, calcifediol treatment of COVID-19 patients in the COVIDIOL pilot randomized clinical trial in Spain found a significant reduction in progression to an ICU [odds ratio (OR) = 0.02 (95%CI, 0.003 to 0.25)] (3), albeit with some controversy relating to trial design (4) . The primary difference between the two trials was that the first week's calcifediol dose in Spain was 1.064 mg while in Iran, it was 0.175 mg. Calcifediol increases serum 25(OH)D concentration by a factor of about three higher than does vitamin D3. Thus, the weekly dose in Spain was approximately equivalent to 43,000 IU vitamin D3, while it is notable that the dose used in the Iranian trial was considerably lower and approximately equivalent to 7000 IU vitamin D3.

The first task for vitamin D in reducing risk of COVID-19 is to reduce the viability and replication of the SARS-CoV-2 virus. This can be done through induction of antimicrobial peptides such as cathelicidin (LL-37) and defensins. Their mechanisms include direct binding to virons, binding to and modulating host cell-surface receptors, blocking viral replication, and functioning as chemokines to enhance or curb adaptive immune responses (5) .

A retrospective observational analysis of SARS-CoV-2 positivity with respect to serum 25(OH)D concentration measurements in the U.S. reported that vitamin D is effective at reducing SARS-CoV-2 infection (6) . Those who achieved 55 ng/ml had about half the SARS-CoV-2 positivity of those with <20 ng/ml.

The second task of vitamin D is to reduce risk of the "cytokine storm" that is associated with COVID-19-induced acute respiratory distress syndrome (ARDS), which can lead to severe multiorgan damage. A review outlined the evidence for the possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection, based on the concept of "inflameaging" (7) . The mechanisms include disrupted immunologic responses in adults with severe COVID-19, an increased concentration of angiotensin-converting enzyme 2 (ACE2) receptor, excess production of reactive oxygen species, decreased autophagy, increased accumulation of senescent cells, and immune senescence. In addition, there can be reduced 25(OH)D concentrations, reducing the body's ability to dampen the production of inflammatory cytokines and reduce the immunomodulatory effects that vitamin D may exert.

A number of studies have reported that the risk and severity of COVID-19 is inversely correlated with serum 25(OH)D concentrations. A study was reported involving 464 participants who tested positive for SARS-CoV-2 in two main hospitals in the United Arab Emirates and had blood drawn for serum 25(OH)D assays at the first hospital visit (8) . Only serum 25(OH)D <12 ng/ml was significantly associated with COVID-19 severity [adjusted OR = 1.76 (95% CI, 1.19 to 2.61, p = 0.005)] and mortality [adjusted OR = 2.58 (95% CI, 1.01 to 6.62, p = 0.048)]. An observational study was conducted in Boston involving 287 COVID-19 patients, 136 of whom were 65 years or older, who had serum 25(OH)D concentration measured within one year prior to testing positive for SARS-CoV-2 (9). The most important finding was that risk of death was greatly reduced for those with 25(OH)D >30 ng/ml and BMI <30 kg/m 2 [adjusted OR = 0.18 (95% CI, 0.04 to 0.84)]. For those >65 years, risk of death, ARDS, and sever sepsis/septic shock were significantly reduced. However, many adverse outcomes were not significantly reduced with 25(OH)D >30 ng/ml.

A meta-analysis of 43 observational studies with a total of 612,601 patients published by January 31, 2021 found among subjects with vitamin D deficiency [25(OH)D <20 ng/ml], risk of COVID-19 infection was higher compared to those with 25(OH)D >30 ng/ml (OR = 1.26; 95% CI, 1.19-1.34; p < 0.01). Vitamin D deficiency was also associated with worse severity and higher mortality than in nondeficient patients (OR = 2.6; 95% CI, 1.84 to 3.67; p < 0.01 and OR = 1.22; 95% CI, 1.04 to 1.43; p < 0.01, respectively) (10).

A therapeutic role for vitamin D amid the COVID-19 pandemic has also been suggested and a few studies have reported the outcomes of treating COVID-19 patients with vitamin D3. Results were reported recently on the 3-month survival of hospitalized geriatric COVID-19 patients supplemented with vitamin D on a regular basis prior to or during the pandemic. Either various bolus doses (i.e., 50,000 IU per month, or 80,000 IU or 100,000 IU or 200,000 IU every 2-3 months) or daily supplementation with 800 IU was administered (11) . The comparator group did not take vitamin D supplements. It was observed that 76 % (n = 51) of participants survived at three months in the intervention group, compared to only 54 % (n = 15) in the comparator group (P = 0.03). The fully-adjusted hazard ratio for 3-month mortality was HR = 0.23 (95% CI: 0.09 to 0.58, p = 0.002) in the intervention group compared to the comparator group.

Another recent study from Turkey included 207 hospitalized patients with COVID-19 pneumonia (12) . Thirty seven of the patinents, those with low 25(OH)D concentration, were given 300,000 IU vitamin D supplement. Those so supplemented had a mean achieved 25(OH)D concentration of 51±16 ng/ml compared to 17±6 ng/ml for those not supplemented. The only significant finding was that only 3% of those supplemented with vitamin D died compared to 14% of those not supplemented (p = 0.04). Other factors that might affect mortality, such as presence of comorbidity or biochemical parameters at admission, were not significantly different between the two groups.

Conflicting results have also been reported. A meta-analyses of five studies, including some of those discussed in this manuscript, reported no significant differences on major health outcomes in response to treatment of COVID-19 with vitamin D (13) . However, the one thing all of these trials have in common is that all of their dosing regimens vary, the time of administration varies, and the main primary and secondary outcomes vary among other differences. Therefore, future trials must consider these factors in their trial designs.

While it seems that sufficient vitamin D status does reduce the risk of SARS-CoV-2 infection susceptibility, COVID-19 and its severity, collectively vitamin D does not seem to provide full protection. However, its role as an adjuvant in treating those with COVID-19 would likely be beneficial (14) . The more extensive review of vitamin D and its potential benefit for the COVID-19 pandemic that appeared in Endocrine Practice earlier this year (15) recommends maintaining serum 25(OH)D concentration above 30 ng/ml and preferably 40 to 60 ng/ml. To achieve these concentrations an adult would require 4000 to 6000 IU/d vitamin D. Those who would benefit the most include the elderly and those with existing chronic diseases.

It has been reported that many have sought additional protection via the use supplements and neutraceuticals to reduce risk of SARS-CoV-2 and COVID-19. Indeed, minerals such as selenium and zinc as well as vitamins C and E, and omega-3 fatty acids saw increases in sales during the intial waves of the COVID-19 pandemic (16) . These supplements and nutraceuticals have been associated with improved immune support, reduced inflammation, and reduced risk of other viral infections. Consequently, these products are currently under investigation for their prophylactic effects against COVID-19 (16) . Indeed, it would be pertinent to maintain a healthy diet and lifestyle due to the links between nutritional status, immune function, and patient outcomes in order to maintain sufficient levels of key nutrients such as vitamin D (16) .

In terms of the therapeutic application of vitamin D, larger double-blind, randomized controlled trials are required. The Maghbooloi et al. study (1) indicates that oral administration of calcifediol does ameliorate vitamin D insufficiency/deficiency and can alter immune function. However, similarly to previous trials investigating the therapeutic potential of calcifediol reviewed in this manuscript, this study only reported modest improvements in clinical outcomes. The advantage of using calcifediol instead of vitamin D3 is that serum 25(OH)D concentrations are increased in a matter of a few hours rather than a few days. Since many who develop COVID-19 wait a few days before seeking medical treatment, and since the beneficial effects of vitamin D occur early in the COVID-19 trajectory, calcifediol should be preferred. Therefore, the quest continues to determine if vitamin D is of therapeutic value against COVID-19.

Disclosure: WBG's nonprofit organization, Sunlight, Nutrition and Health Research Center, receives funding from Bio-Tech Pharmacal, Inc. (Fayetteville, AR). LR has no conflicts of interest to declare.

Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood neutrophil-to-lymphocyte ratio marker of disease severity in patients hospitalized with COVID-19: a pilot, multicenter, randomized, placebo-controlled double blind clinical trial

Evidence That Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths

Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study

Notable Developments for Vitamin D Amid the COVID-19 Pandemic, but Caution Warranted Overall: A Narrative Review

Ramping Up Antimicrobial Peptides Against Severe Acute Respiratory Syndrome Coronavirus-2

SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels

The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflameaging

COVID-19 Disease Severity and Death in Relation to Vitamin D Status among SARS-CoV-2-Positive UAE Residents

Association of Vitamin D Status With Hospital Morbidity and Mortality in Adult Hospitalized Patients With COVID-19

Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies

Vitamin D supplementation prior to or during COVID-19 associated with better 3-month survival in geriatric patients: Extension phase of the GERIA-COVID study

The prognostic significance of vitamin D deficiency in patients with COVID-19 pneumonia

Vitamin D supplementation and COVID-19 treatment: A systematic review and meta-analysis

Clinical aspects of SARS-CoV-2 infection and vitamin D : COVID-19 and the endocrine system: special issue for reviews in endocrine and metabolic disorders (Felipe Casaneuva, Editor in Chief) A. Giustina and JP Bilezikian, Guest Editors

Vitamin D and Its Potential Benefit for the COVID-19 Pandemic

Dietary Supplements and Nutraceuticals under Investigation for COVID-19 Prevention and Treatment. mSystems